This study assessed the impact of hyperpolypharmacy on hospital readmission risk in 2 Medicare populations and identified effects of postdischarge ambulatory care.
Trudy M. Krause, DrPH
Advertisement
Articles by Trudy M. Krause, DrPH
Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
This study explored the statistical association of key social determinants of health with specific health outcomes to validate impact and then created weighted categorical matrices.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
5